Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance

HIV Medicine

Volumn 3, Issue 4, 2002, Pages 239-246

  Worm, D ^a   Kirk, O ^b   Andersen, O ^b   Vinten, J ^a   Gerstoft, J ^b   Katzenstein, T L ^b   Nielsen, H ^c   Pedersen, C ^d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

HIV; Lipoatrophy; Nucleoside reverse transcriptase inhibitor; Protease inhibitor

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CHOLESTEROL; INDINAVIR; LOW DENSITY LIPOPROTEIN; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; BODY FAT; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPID METABOLISM; LIPOATROPHY; LIPOPROTEIN BLOOD LEVEL; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY COMPOSITION; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; GLUCOSE INTOLERANCE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV WASTING SYNDROME; HUMANS; HYPERLIPIDEMIAS; INDINAVIR; LIPODYSTROPHY; MALE; MIDDLE AGED; QUESTIONNAIRES; RITONAVIR; SAQUINAVIR; STAVUDINE;

EID: 18744404775     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2002.00125.x     Document Type: Article

References (22)

1. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998; 12: F37-F39.
2. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with the use of indinavir. Lancet 1998; 351: 871-875.
3. Carr A, Cooper DA. Lipodystrophy associated with an HIV-protease inhibitor. N Engl J Med 1998; 339: 1296.
4. Herry I, Bernard L, de Truchis P, Perronne C. Hypertrophy of the breasts in a patient treated with indinavir. Clin Infect Dis 1997; 25: 937-938.
5. Lo JC, Mulligan K, Tai VW et al. 'Buffalo hump' in men with HIV-1 infection. Lancet 1998; 351: 867-870.
6. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
7. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093-2099.
8. Martinez E, Mocroft A, García-Viejo MA et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001; 357: 592-598.
9. Saint-Marc T, Partisani M, Poizot-Martin I et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000; 14: 37-49.
10. Domingo P, Guardiola JM, Ris J, Nolla J. The impact of new antiretroviral regiments on HIV-related hospital admissions and deaths. AIDS 1998; 12: 529-530.
11. Dubé MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor-associated hyperglycaemia. Lancet 1997; 350: 713-714.
12. Walli R, Herfort O, Gerlinde M et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998; 12: F167-F173.
13. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275: 20251-20254.
14. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351: 1881-1883.
15. Wentworth JM, Burris TP, Chatterjee VK. HIV protease inhibitors block human preadipocyte differentiation, but not the PPARgamma/RXR heterodimer. J Endocrinol 2000; 164: R7-R10.
16. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354: 1112-1115.
17. Kirk O, Katzenstein TL, Gerstoft J et al. Combination therapy containing ritonavir plus saquinavir has superior short-term efficacy: a randomised trial. AIDS 1999; 13: F9-F16.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment. insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
19. Saint-Marc T, Partisani M, Poizot-Martin I et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13: 1659-1667.
20. Mercie P, Tcamgoue S, Dabis F, Pellegrin JL. Lipodystrophy in HIV-1-infected patients. Lancet 1999; 354: 867-868.
21. Røge BT, Katzenstein T, Gerstoft J. Comparison of P-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir. Scand J Infect Dis 2001; 33: 306-311.
22. Carr A. An objective case definition of HIV lipodystrophy. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, February 2002 [Abstract 31].